课题基金 / 基金详情

Genetic and Signaling Pathways in Epithelial Thyroid Cancer

Genetic and Signaling Pathways in Epithelial Thyroid Cancer
上皮性甲状腺癌的遗传和信号通路
批准号:
8064255
负责人:
Matthew D Ringel
金额:
$224.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-03-01 至 2013-02-28

项目摘要

项目成果

Matthew D Ringel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The incidence of thyroid cancer is rising at the second fastest rate of all malignancies in the United States and has an increasing tumor-specific mortality annually, making it an important public health problem. The reasons for this increasing incidence and rising death rate are uncertain. The goal of the P01 application is to address the key issues relating to thyroid cancer predisposition, tumorigenesis, and progression in order to enhance the potential for both early diagnosis and the effective treatment of progressive disease. Based on extensive preliminary data from our group, we propose to: (1) examine and identify predisposing genes for papillary thyroid cancer, (2) determine the critical changes responsible for the development of follicular thyroid cancer in an inherited form of the disease, Cowden syndrome, using a novel animal model, and translate this into a scheme to enhance preoperative diagnosis of this form of thyroid cancer, (3) evaluate and identify the key mechanisms of thyroid cancer induction and dedifferentiation induced by the RET/PTC 1 oncogene, one of the most common genetic abnormalities in papillary thyroid cancer, using a second novel animal model system, and (4) determine key pathways involved in tumor invasion and motility for both follicular and papillary thyroid cancers focusing on the models developed in this P01, and then test novel agents directed at blocking these pathway in vitro and in vivo. Over the past six years, the PI's of the individual projects, and the leaders of the cores have created an environment to successfully perform this integrated P01 that is unique for thyroid cancer. This includes a substantial database, integration with pathology, and a record of successful collaborative genetics, laboratory, drug development, and clinical research as evidenced by approximately thirty co-authored publications. Thus, this P01 represents an integrated Bedside-to-Bench-to-Bedside approach targeting the key clinical issues confronting the diagnosis and management of patients with thyroid cancer.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RCAN 1.4 metastasis suppressor in thyroid cancer
  • 批准号:
    9973560
  • 项目类别:
  • 资助金额:
    $45.25万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Ringel
  • 依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
  • 批准号:
    10604328
  • 项目类别:
  • 资助金额:
    $44.53万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Ringel
  • 依托单位:
RCAN 1.4 metastasis suppressor in thyroid cancer
  • 批准号:
    10400004
  • 项目类别:
  • 资助金额:
    $44.34万
  • 财政年份:
    2020
  • 负责人:
    Matthew D Ringel
  • 依托单位:
Role of p21-activated kinases in thyroid cancer
  • 批准号:
    10377551
  • 项目类别:
  • 资助金额:
    $36.76万
  • 财政年份:
    2018
  • 负责人:
    Matthew D Ringel
  • 依托单位:
国内基金
海外基金
USP51/Zeb1 signaling调控乳腺癌化疗耐药的病理机制及其靶向干预研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    杨爽
  • 依托单位:
Zeb1/IL-8 signaling调控乳腺癌免疫微环境重塑的机制研究
  • 批准号:
    81972454
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2019
  • 负责人:
    杨爽
  • 依托单位:
Ptch1 基因通过 Hh 信号通路(Hedgehog signaling pathway)对卵巢癌细胞增殖和凋亡的影响
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    3.0万元
  • 批准年份:
    2019
  • 负责人:
  • 依托单位:
    --
HBx-FXR signaling相关LncRNA在原发性肝癌中的作用及机制研究
  • 批准号:
    81772972
  • 项目类别:
    面上项目
  • 资助金额:
    50.0万元
  • 批准年份:
    2017
  • 负责人:
    牛永东
  • 依托单位: